FibroBiologics (FBLG)
Market Price (2/27/2026): $0.291 | Market Cap: $12.5 MilSector: Health Care | Industry: Biotechnology
FibroBiologics (FBLG)
Market Price (2/27/2026): $0.291Market Cap: $12.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Cellular & Regenerative Medicine, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -133%, 3Y Excs Rtn is -172% | Penny stockMkt Price is 0.3 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 | ||
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -18 Mil | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -158% | ||
| High stock price volatilityVol 12M is 107% | ||
| Key risksFBLG key risks include [1] significant funding pressure from high debt and negative cash flow, Show more. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Cellular & Regenerative Medicine, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -133%, 3Y Excs Rtn is -172% |
| Penny stockMkt Price is 0.3 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -18 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -158% |
| High stock price volatilityVol 12M is 107% |
| Key risksFBLG key risks include [1] significant funding pressure from high debt and negative cash flow, Show more. |
Qualitative Assessment
AI Analysis | Feedback
FibroBiologics (FBLG) stock has lost about 30% since 10/31/2025 because of the following key factors:
1. Significant Widening of Net Losses and High Burn Rate. FibroBiologics reported a net loss that widened to $18.6 million for the full year 2025, a substantial increase from $11.2 million in 2024. This was largely driven by increased research and development expenses, which rose to $7.4 million in 2025 from $4.5 million in 2024, indicating a high cash burn for a pre-revenue company.
2. Challenging Liquidity Position and Shareholder Dilution. The company maintained a low cash and cash equivalents balance of approximately $4.9 million at the end of 2025, which management acknowledged could constrain near-term operations without additional funding. To address capital needs, FibroBiologics raised $7.2 million through multiple direct offerings in 2025, leading to a substantial 79.1% dilution of shares outstanding over the past year.
Show more
1. Significant Widening of Net Losses and High Burn Rate. FibroBiologics reported a net loss that widened to $18.6 million for the full year 2025, a substantial increase from $11.2 million in 2024. This was largely driven by increased research and development expenses, which rose to $7.4 million in 2025 from $4.5 million in 2024, indicating a high cash burn for a pre-revenue company.
2. Challenging Liquidity Position and Shareholder Dilution. The company maintained a low cash and cash equivalents balance of approximately $4.9 million at the end of 2025, which management acknowledged could constrain near-term operations without additional funding. To address capital needs, FibroBiologics raised $7.2 million through multiple direct offerings in 2025, leading to a substantial 79.1% dilution of shares outstanding over the past year.
Show more
Stock Movement Drivers
Fundamental Drivers
The -28.1% change in FBLG stock from 10/31/2025 to 2/26/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 2262026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.39 | 0.28 | -28.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 43 | 43 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 2/26/2026| Return | Correlation | |
|---|---|---|
| FBLG | -28.1% | |
| Market (SPY) | 1.1% | 10.5% |
| Sector (XLV) | 9.1% | 4.5% |
Fundamental Drivers
The -55.6% change in FBLG stock from 7/31/2025 to 2/26/2026 was primarily driven by a -10.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312025 | 2262026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.64 | 0.28 | -55.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 39 | 43 | -10.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2025 to 2/26/2026| Return | Correlation | |
|---|---|---|
| FBLG | -55.6% | |
| Market (SPY) | 9.4% | 12.5% |
| Sector (XLV) | 21.2% | 4.2% |
Fundamental Drivers
The -82.4% change in FBLG stock from 1/31/2025 to 2/26/2026 was primarily driven by a -22.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312025 | 2262026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.61 | 0.28 | -82.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 34 | 43 | -22.2% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2025 to 2/26/2026| Return | Correlation | |
|---|---|---|
| FBLG | -82.4% | |
| Market (SPY) | 15.5% | 10.7% |
| Sector (XLV) | 8.6% | 8.9% |
Fundamental Drivers
nullnull
Market Drivers
1/31/2023 to 2/26/2026| Return | Correlation | |
|---|---|---|
| FBLG | ||
| Market (SPY) | 75.9% | 4.7% |
| Sector (XLV) | 23.5% | 4.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| FBLG Return | - | - | - | -93% | -89% | 17% | -99% |
| Peers Return | -6% | -44% | 67% | -9% | -3% | -8% | -29% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 85% |
Monthly Win Rates [3] | |||||||
| FBLG Win Rate | - | - | - | 25% | 17% | 50% | |
| Peers Win Rate | 52% | 38% | 55% | 47% | 43% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| FBLG Max Drawdown | - | - | - | -96% | -89% | 0% | |
| Peers Max Drawdown | -20% | -54% | -17% | -38% | -35% | -17% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VCEL, IART, MDXG, ORGO, CRSP.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/26/2026 (YTD)
How Low Can It Go
FBLG has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to VCEL, IART, MDXG, ORGO, CRSP
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About FibroBiologics (FBLG)
We are a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and for potential extension of life applications including thymic and splenic involution reversal. In connection with our formation, we issued shares of our Series A Preferred Stock, or the Series A Preferred Stock, to our then parent, SpinalCyte LLC (doing business as FibroGenesis), or FibroGenesis, in return for rights to certain intellectual property through a patent assignment agreement and an intellectual property cross-licensing agreement. Developing the intellectual property obtained from FibroGenesis was the basis for our formation. Prior to our inception, preclinical research and development related to the transferred intellectual property took place under FibroGenesis. Fibroblasts Technology Platform Fibroblasts and stem cells are the only two cell types in the human body that can regenerate tissue and organs. Studies have indicated that mesenchymal stem cells and fibroblasts share many surface markers in common, and can differentiate into many cells including adipocytes, chondrocytes, osteoblasts, hepatocytes, and cardiomyocytes, and can regulate the immune system. However, transcriptomic and epigenetic studies have indicated a clear difference between the two cell types. Fibroblasts comprise the main cell type of connective tissue, possessing a spindle-shaped morphology, whose classical function has historically been believed to produce an extracellular matrix responsible for maintaining the structural integrity of the tissue. Fibroblasts also play an important role in maintaining stem cell niches in organs and are involved in every stage of wound healing. Fibroblasts are favorable to stem cells as a cell therapy treatment platform because fibroblasts: . can be non-invasively harvested from a variety of skin donors from surgical procedures such as tummy tuck flaps or simple biopsy punch; . have a faster doubling time in culture than stem cells; . possess superior immune modulatory activity compared with stem cells; . exhibit enhanced ability to produce regenerative cytokines and growth factors compared with stem cells; and . are more economical to isolate, culture and expand compared with stem cells because fibroblasts do not require the use of expensive tissue culture media and additives. Studies have demonstrated that allogeneic fibroblasts, much like mesenchymal stem cells, are immune-privileged and do not provoke an immune response in vitro and in vivo. If autologous fibroblasts were required instead, it would mean that cells would have to be harvested from each patient, processed and cultured, and then administered to the same patient, which would be more costly and inefficient. Because allogeneic fibroblasts do not cause an immune response, we are planning to build our own current Good Manufacturing Practices, or cGMP, manufacturing facility to source allogeneic fibroblast cells for clinical testing of our product candidates and for commercial sales if our product candidates receive marketing approval. To date, however, no fibroblast therapy products have been approved and there have only been a few clinical trials involving fibroblasts. The costs to develop, manufacture, and commercialize product candidates utilizing our fibroblasts technology platform may exceed our estimates. Furthermore, the biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates so any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We were formed in April 2021 as a Texas limited liability company under the name FibroBiologics, LLC, and converted to a Delaware corporation in December 2021 under the name Fibrobiologics, Inc. On April 12, 2023, we changed our name to FibroBiologics, Inc. Our principal executive offices are located at 455 E. Medical Center Blvd., Suite 300, Houston, Texas.
AI Analysis | Feedback
Here are 1-2 brief analogies for FibroBiologics (FBLG):
- Like a Vertex Pharmaceuticals or Regeneron, but singularly focused on fibroblast cell therapies for chronic diseases.
- A platform biotech company similar to Moderna (mRNA) or CRISPR Therapeutics (gene editing), but built around fibroblast cell therapies.
AI Analysis | Feedback
- FM101: A fibroblast cell therapy candidate currently in clinical trials for the treatment of chronic low back pain and disc degeneration.
- FM501: A preclinical fibroblast cell therapy candidate being developed for multiple sclerosis.
- FM301: A preclinical fibroblast cell therapy candidate aimed at treating Duchenne muscular dystrophy.
- Oncology Pipeline (e.g., FM401): Preclinical fibroblast cell therapy candidates exploring applications in various cancers.
- Inflammation & Fibrosis Pipeline (e.g., FM201, FM601): Preclinical fibroblast cell therapy candidates targeting inflammatory bowel disease, acute respiratory distress syndrome, and idiopathic pulmonary fibrosis.
AI Analysis | Feedback
FibroBiologics (FBLG) Major Customers
FibroBiologics (symbol: FBLG) is a clinical-stage biotechnology company primarily focused on the research and development of fibroblast cell therapies for chronic diseases. As a company in the clinical development phase, FibroBiologics does not currently have any commercial products approved for sale on the market.
Consequently, FibroBiologics does not generate revenue from the sale of products or services and, therefore, does not have traditional "major customers" (either other companies or individuals) purchasing its therapies or services at this time. Their current activities are centered around clinical trials and seeking regulatory approvals for their investigational therapies.
AI Analysis | Feedback
- Lonza (LONN)
AI Analysis | Feedback
Pete O'Heeron, Chief Executive Officer
Mr. O'Heeron is the Founder, Chairman, and CEO of FibroBiologics. He has over 25 years of experience in medical technology and biotech development and holds more than 350 patents. Prior to founding FibroBiologics/FibroGenesis, LLC, he founded Advanced Medical Technologies, LLC, an operational investment group focused on early-stage medical opportunities. He also founded NeoSurg Technologies, which developed the T2000 Minimally Invasive Access System, and successfully sold NeoSurg Technologies to Cooper Surgical in 2006.
Jason D. Davis, Chief Financial Officer
Mr. Davis was appointed Chief Financial Officer effective June 9, 2025, bringing over 20 years of public company and capital markets experience. He most recently served as Chief Financial Officer of Virax Biolabs, where he guided the company through a successful IPO in July 2022 and led multiple capital raises. Before Virax, Mr. Davis held various finance roles at public companies, including HyperDynamics Corp, where he contributed to increasing the company's market cap from $20 million to over $700 million and raising more than $200 million from U.S. and European capital markets.
Hamid Khoja, Ph.D., Chief Scientific Officer
Dr. Khoja serves as the Chief Scientific Officer of FibroBiologics. He co-authored an opinion editorial with CEO Pete O'Heeron, highlighting the therapeutic advantages of fibroblast cells over traditional stem cell therapies.
Ruben A. Garcia, General Counsel
Mr. Garcia was appointed General Counsel in March 2024. He has more than 20 years of experience in legal leadership within the pharmaceutical industry. His prior roles include Senior Vice President, General Counsel and Corporate Secretary at AcelRx Pharmaceuticals, Inc. (now Talphera, Inc.), and Senior Corporate Counsel and Assistant Secretary for Ultragenyx Pharmaceutical Inc.
Richard M. Silver, M.D., Co-Founder
Dr. Silver is a Co-Founder of FibroBiologics. He is a Distinguished University Professor and Director of the SmartState Center for Inflammation and Fibrosis Research at the Medical University of South Carolina, where he specializes in inflammation and fibrosis research.
AI Analysis | Feedback
For FibroBiologics (FBLG), key business risks include:
- Liquidity and Capital Resources: FibroBiologics faces significant risks related to its liquidity and its ability to maintain sufficient capital resources to fund its operations and advance its pipeline. The company is in a pre-revenue stage, has a high debt-to-equity ratio of 302.81%, and reported a negative annual cash flow of $17.74 million, leading to ongoing funding pressure. While a recent $1.7 million offering was completed, additional financing, which may result in shareholder dilution, is anticipated to be necessary. As of September 30, 2025, FibroBiologics had approximately $4.9 million in cash and cash equivalents.
- Clinical Trial Success and R&D Risks: As a clinical-stage biotechnology company, the success of FibroBiologics' research and development efforts and subsequent clinical trials is critical. There is an inherent and unpredictable relationship between preclinical study results and the outcomes of clinical trials. The company's plans to initiate Phase 1/2 trials for its treatments mean that failure in these trials could lead to a further decline in stock value and jeopardize the business model.
- Stock Volatility and Decline: FibroBiologics has experienced substantial stock price volatility and a significant decline, with its shares falling by 92.93% over the past year. The stock is characterized as "very high risk" due to its high volatility and periods of low trading volume, which can impact investor confidence and the company's ability to raise capital. A recent share offering at a lower price point may also suggest an undervaluation of the company's stock and weak market confidence.
AI Analysis | Feedback
null
AI Analysis | Feedback
FibroBiologics (FBLG) is developing treatments for several chronic diseases, with the following addressable market sizes identified:
- Degenerative Disc Disease (DDD): The addressable market size is estimated at $26 billion (U.S.), with 1.2 million surgeries performed annually in the U.S.
- Psoriasis: This condition impacts 123 million people worldwide, with 7 million affected in the U.S.
- Diabetic Foot Ulcers (DFU): While FibroBiologics is preparing for a Phase 1/2 clinical trial for diabetic foot ulcers, specific market size figures for this product were not provided in the available information.
- Multiple Sclerosis (MS): FibroBiologics is developing therapies for multiple sclerosis; however, specific market size figures for this product were not provided in the available information.
AI Analysis | Feedback
FibroBiologics (FBLG), a clinical-stage biotechnology company, is not currently generating revenue, with analysts forecasting zero revenue for 2025, 2026, and 2027. Therefore, the expected drivers of future revenue growth over the next 2-3 years are intrinsically linked to the advancement and potential future commercialization of its pipeline of fibroblast-based therapies. Key drivers include:
- Advancement of CYWC628 for Diabetic Foot Ulcers (DFU) through clinical trials: The initiation of a Phase 1/2 clinical trial in Australia evaluating the fibroblast-based spheroids product candidate, CYWC628, in DFU patients is expected in the first quarter of 2026, with completion anticipated in the third quarter of 2026. Successful progression through these clinical stages is a critical step towards eventual market approval and revenue generation.
- Completion of pre-clinical studies for CYPS317 in Psoriasis: FibroBiologics expects to complete pre-clinical IND-enabling studies for CYPS317, a fibroblast spheroid product candidate for the treatment of psoriasis, by the end of 2025. Positive outcomes from these studies could lead to the initiation of human clinical trials, further advancing the product towards potential commercialization.
- Development of CybroCell™ for Degenerative Disc Disease: The company has confirmed the use of its proprietary CYWC628 master cell bank for the manufacturing of CybroCell™, an investigational intradiscal administered allogeneic fibroblast cell-based therapy for degenerative disc disease. Advancing this therapy through preclinical and clinical development represents another potential significant revenue stream in the future.
AI Analysis | Feedback
Share Issuance
- FibroBiologics entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN LTD. for up to $25 million in common stock over two years.
- The company received $15 million in three equal tranches of convertible promissory notes from this agreement, with an additional $10 million available subject to conditions.
- During 2025, $9.7 million of notes converted into 13,059,270 shares, increasing shares outstanding to 51,456,077 by October 31, 2025.
Inbound Investments
- FibroBiologics secured up to $25 million through a Standby Equity Purchase Agreement with Yorkville, with $15 million already received in tranches.
Capital Expenditures
- Research and development expenses increased to approximately $6.6 million for the nine months ended September 30, 2025, from $3.1 million in the same period of 2024, driven by contract research, CRO costs for clinical trials, lab facilities, personnel, and research materials.
- The net proceeds from the $25 million financing are expected to fund research and development programs and support the upcoming Phase 1/2 diabetic foot ulcer clinical trial.
- The company completed its proprietary master cell bank in February 2025 to support upcoming clinical trials, and aims for manufacturing runs and cGMP completion by the end of 2025.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| FibroBiologics Stock Surges 54%, With A 7-Day Winning Spree | 12/13/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to FBLG.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | ABT | Abbott Laboratories | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 5.0% | 5.0% | -1.0% |
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -13.5% | -13.5% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 16.0% | 16.0% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.5% | 12.5% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -40.9% | -40.9% | -42.4% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 8.13 |
| Mkt Cap | 0.8 |
| Rev LTM | 326 |
| Op Inc LTM | 4 |
| FCF LTM | -16 |
| FCF 3Y Avg | -2 |
| CFO LTM | 21 |
| CFO 3Y Avg | 23 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.0% |
| Rev Chg 3Y Avg | 17.4% |
| Rev Chg Q | 16.6% |
| QoQ Delta Rev Chg LTM | 3.9% |
| Op Mgn LTM | 2.3% |
| Op Mgn 3Y Avg | 3.4% |
| QoQ Delta Op Mgn LTM | 2.0% |
| CFO/Rev LTM | 11.3% |
| CFO/Rev 3Y Avg | 10.4% |
| FCF/Rev LTM | 3.5% |
| FCF/Rev 3Y Avg | 2.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.8 |
| P/S | 1.4 |
| P/EBIT | 6.4 |
| P/E | 8.6 |
| P/CFO | 4.5 |
| Total Yield | -4.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 0.4% |
| D/E | 0.1 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -2.5% |
| 3M Rtn | -10.2% |
| 6M Rtn | -25.7% |
| 12M Rtn | -33.5% |
| 3Y Rtn | 13.7% |
| 1M Excs Rtn | -1.5% |
| 3M Excs Rtn | -9.2% |
| 6M Excs Rtn | -30.1% |
| 12M Excs Rtn | -49.1% |
| 3Y Excs Rtn | -52.1% |
Price Behavior
Price Behavior
| Market Price | $0.28 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 01/31/2024 | |
| Distance from 52W High | -79.5% | |
| 50 Days | 200 Days | |
| DMA Price | $0.29 | $0.50 |
| DMA Trend | down | down |
| Distance from DMA | -1.0% | -43.5% |
| 3M | 1YR | |
| Volatility | 140.1% | 107.0% |
| Downside Capture | 283.03 | 245.85 |
| Upside Capture | 285.02 | 67.49 |
| Correlation (SPY) | 9.1% | 13.1% |
FBLG Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.01 | -0.64 | 0.71 | 1.10 | 0.56 | 0.24 |
| Up Beta | -11.45 | -6.85 | -7.03 | -3.16 | 0.05 | -0.69 |
| Down Beta | 0.55 | -4.39 | 0.61 | 1.38 | 0.29 | -0.09 |
| Up Capture | 1018% | 566% | 289% | 117% | 22% | -5% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 10 | 22 | 33 | 57 | 107 | 221 |
| Down Capture | 111% | 251% | 312% | 279% | 151% | 108% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 10 | 19 | 28 | 68 | 141 | 274 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FBLG | |
|---|---|---|---|---|
| FBLG | -73.0% | 107.4% | -0.72 | - |
| Sector ETF (XLV) | 7.2% | 17.3% | 0.24 | 9.3% |
| Equity (SPY) | 17.1% | 19.4% | 0.69 | 12.9% |
| Gold (GLD) | 79.3% | 25.7% | 2.25 | 9.6% |
| Commodities (DBC) | 10.9% | 16.8% | 0.45 | 7.3% |
| Real Estate (VNQ) | 6.6% | 16.6% | 0.21 | 7.9% |
| Bitcoin (BTCUSD) | -23.4% | 45.1% | -0.46 | 18.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FBLG | |
|---|---|---|---|---|
| FBLG | -60.4% | 152.5% | -0.77 | - |
| Sector ETF (XLV) | 8.2% | 14.5% | 0.38 | 4.1% |
| Equity (SPY) | 13.6% | 17.0% | 0.63 | 4.7% |
| Gold (GLD) | 23.6% | 17.2% | 1.12 | 2.0% |
| Commodities (DBC) | 10.8% | 19.0% | 0.45 | -0.6% |
| Real Estate (VNQ) | 5.3% | 18.8% | 0.19 | 3.5% |
| Bitcoin (BTCUSD) | 4.0% | 57.0% | 0.29 | 7.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with FBLG | |
|---|---|---|---|---|
| FBLG | -37.0% | 152.5% | -0.77 | - |
| Sector ETF (XLV) | 10.9% | 16.5% | 0.55 | 4.1% |
| Equity (SPY) | 15.5% | 17.9% | 0.74 | 4.7% |
| Gold (GLD) | 15.1% | 15.6% | 0.81 | 2.0% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | -0.6% |
| Real Estate (VNQ) | 6.6% | 20.7% | 0.28 | 3.5% |
| Bitcoin (BTCUSD) | 66.3% | 66.8% | 1.06 | 7.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.